Experienced in Peripheral T-Cell Lymphoma

Tamar Tadmor

Efron St 1, 
Haifa, HA, IL 
Experienced in Peripheral T-Cell Lymphoma
Efron St 1, 
Haifa, HA, IL 
OverviewLocationsClinical Research

Overview

Tamar Tadmor practices in Haifa, Israel. Ms. Tadmor is rated as an Experienced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 186 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Peripheral T-Cell Lymphoma.

Gender
Female

Locations

Efron St 1, Haifa, HA 35254, Israel
Other Locations
47, Golomb Street, Haifa, HA 31048, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome. GIVeRS Protocol: On Behalf of the Israeli CLL Study Group
A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome. GIVeRS Protocol: On Behalf of the Israeli CLL Study Group
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Combination product
Study Drugs: Obinutuzumab, Ibrutinib, Venetoclax
Study Phase: Phase 2
View 2 Less Clinical Trials

186 Total Publications

Expert consensus opinion on the management of hairy cell leukemia in elderly patients.
Expert consensus opinion on the management of hairy cell leukemia in elderly patients.
Journal: Leukemia & lymphoma
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tadmor's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 39 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile